---
figid: PMC7608616__41419_2020_3144_Fig3_HTML
figtitle: Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7608616
filename: 41419_2020_3144_Fig3_HTML.jpg
figlink: pmc/articles/PMC7608616/figure/Fig3/
number: F3
caption: The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits the PI3K and the mTOR pathway,
  which interferes with MCL-1 stability, thereby releasing BIM to activate BAX/BAK,
  leading to cytochrome c release and apoptosis. Inhibition of PI3Kδ by idelalisib
  and AKT by ibrutinib and MK2206 further blocks the PI3K/AKT-mediated signaling.
  Inhibition of these pathways reduces MCL-1 levels, leading to BIM release and apoptosis.
papertitle: Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
reftext: Isha Kapoor, et al. Cell Death Dis. 2020 Nov;11(11):941.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9397776
figid_alias: PMC7608616__F3
figtype: Figure
redirect_from: /figures/PMC7608616__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7608616__41419_2020_3144_Fig3_HTML.html
  '@type': Dataset
  description: The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits the PI3K and the mTOR
    pathway, which interferes with MCL-1 stability, thereby releasing BIM to activate
    BAX/BAK, leading to cytochrome c release and apoptosis. Inhibition of PI3Kδ by
    idelalisib and AKT by ibrutinib and MK2206 further blocks the PI3K/AKT-mediated
    signaling. Inhibition of these pathways reduces MCL-1 levels, leading to BIM release
    and apoptosis.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - RPTOR
  - AKT1
  - AKT2
  - AKT3
  - GSK3B
  - PTEN
  - BCL2L11
  - BAK1
  - BAX
  - BCL2
  - BEZ-235H
  - Ibrutinib
---
